Global Neuromyelitis Optica Drug Market 2026 by Company, Regions, Type and Application, Forecast to 2032
According to our (Global Info Research) latest study, the global Neuromyelitis Optica Drug market size was valued at US$ 52.67 million in 2025 and is forecast to a readjusted size of US$ 64.33 million by 2032 with a CAGR of 2.9% during review period.
Neuromyelitis optica (NMO) is an uncommon disease syndrome of the central nervous system (CNS) that affects the optic nerves and spinal cord. Individuals with NMO develop optic neuritis, which causes pain in the eye and vision loss, and transverse myelitis, which causes weakness, numbness, and sometimes paralysis of the arms and legs, along with sensory disturbances and loss of bladder and bowel control. NMO leads to loss of myelin, which is a fatty substance that surrounds nerve fibers and helps nerve signals, move from cell to cell. The syndrome can also damage nerve fibers and leave areas of broken-down tissue. In the disease process of NMO, for reasons that aren't yet clear, immune system cells and antibodies attack and destroy myelin cells in the optic nerves and the spinal cord. Neuromyelitis optica drug is drug used in the treatment of neuromyelitis optica, in this report we focused on Glucocorticoids such as Methylprednisolone and Immunoglobulin such as IVIg.
The Neuromyelitis Optica (NMO) drug market is being significantly driven by the rising prevalence and improved diagnosis of this rare autoimmune disorder, also known as Neuromyelitis Optica Spectrum Disorder (NMOSD). Increased awareness among healthcare professionals, coupled with advancements in diagnostic technologies such as AQP4-IgG antibody testing, has led to earlier and more accurate diagnosis of NMO, thereby increasing the number of patients eligible for treatment. Furthermore, the approval of targeted therapies like eculizumab, inebilizumab, and satralizumab in recent years has transformed the treatment landscape, offering more effective and specific interventions compared to traditional immunosuppressants. These breakthroughs have not only improved patient outcomes but have also stimulated investment and innovation in NMO drug development. The growing focus on orphan diseases by pharmaceutical companies, supported by favorable regulatory incentives such as orphan drug designations and fast-track approvals, is further fueling market growth. In addition, increasing healthcare expenditure, especially in developed regions, and a stronger patient advocacy movement are contributing to greater access to treatment and awareness about this once-overlooked condition.
Despite promising developments, the NMO drug market faces several challenges that may hinder its long-term growth. First, the high cost of newly approved biologic therapies poses a significant barrier to access, particularly in low- and middle-income countries where reimbursement systems are weak or nonexistent. The pricing of drugs like eculizumab, which can cost hundreds of thousands of dollars per year, places a heavy burden on both healthcare systems and patients, potentially limiting widespread adoption. Additionally, NMO is a rare and complex disease, which makes it difficult to recruit sufficient participants for large-scale clinical trials, slowing the pace of drug development and innovation. The heterogeneity of disease presentation and overlapping symptoms with multiple sclerosis also pose diagnostic challenges, which can lead to misdiagnosis and inappropriate treatment. Moreover, long-term safety data for newer therapies are still limited, which may create hesitation among clinicians and regulatory bodies when adopting these treatments on a broader scale. Lastly, the market remains highly specialized, with few pharmaceutical players involved, leading to limited competition and potential supply chain vulnerabilities. Addressing these issues will be essential to ensuring that recent advancements in NMO treatment translate into improved outcomes for patients across different healthcare environments.
This report is a detailed and comprehensive analysis for global Neuromyelitis Optica Drug market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Neuromyelitis Optica Drug market size and forecasts, in consumption value ($ Million), 2021-2032
Global Neuromyelitis Optica Drug market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
Global Neuromyelitis Optica Drug market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
Global Neuromyelitis Optica Drug market shares of main players, in revenue ($ Million), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Neuromyelitis Optica Drug
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Neuromyelitis Optica Drug market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Pfizer, Fresenius, Teva, Sandoz, Intas, Gyjtrs, NANG KUANG, Tianjin Kingyork, Baxter, CSL, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Neuromyelitis Optica Drug market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Chapter 1, to describe Neuromyelitis Optica Drug product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Neuromyelitis Optica Drug, with revenue, gross margin, and global market share of Neuromyelitis Optica Drug from 2021 to 2026.
Chapter 3, the Neuromyelitis Optica Drug competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Neuromyelitis Optica Drug market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Neuromyelitis Optica Drug.
Chapter 13, to describe Neuromyelitis Optica Drug research findings and conclusion.
Neuromyelitis optica (NMO) is an uncommon disease syndrome of the central nervous system (CNS) that affects the optic nerves and spinal cord. Individuals with NMO develop optic neuritis, which causes pain in the eye and vision loss, and transverse myelitis, which causes weakness, numbness, and sometimes paralysis of the arms and legs, along with sensory disturbances and loss of bladder and bowel control. NMO leads to loss of myelin, which is a fatty substance that surrounds nerve fibers and helps nerve signals, move from cell to cell. The syndrome can also damage nerve fibers and leave areas of broken-down tissue. In the disease process of NMO, for reasons that aren't yet clear, immune system cells and antibodies attack and destroy myelin cells in the optic nerves and the spinal cord. Neuromyelitis optica drug is drug used in the treatment of neuromyelitis optica, in this report we focused on Glucocorticoids such as Methylprednisolone and Immunoglobulin such as IVIg.
The Neuromyelitis Optica (NMO) drug market is being significantly driven by the rising prevalence and improved diagnosis of this rare autoimmune disorder, also known as Neuromyelitis Optica Spectrum Disorder (NMOSD). Increased awareness among healthcare professionals, coupled with advancements in diagnostic technologies such as AQP4-IgG antibody testing, has led to earlier and more accurate diagnosis of NMO, thereby increasing the number of patients eligible for treatment. Furthermore, the approval of targeted therapies like eculizumab, inebilizumab, and satralizumab in recent years has transformed the treatment landscape, offering more effective and specific interventions compared to traditional immunosuppressants. These breakthroughs have not only improved patient outcomes but have also stimulated investment and innovation in NMO drug development. The growing focus on orphan diseases by pharmaceutical companies, supported by favorable regulatory incentives such as orphan drug designations and fast-track approvals, is further fueling market growth. In addition, increasing healthcare expenditure, especially in developed regions, and a stronger patient advocacy movement are contributing to greater access to treatment and awareness about this once-overlooked condition.
Despite promising developments, the NMO drug market faces several challenges that may hinder its long-term growth. First, the high cost of newly approved biologic therapies poses a significant barrier to access, particularly in low- and middle-income countries where reimbursement systems are weak or nonexistent. The pricing of drugs like eculizumab, which can cost hundreds of thousands of dollars per year, places a heavy burden on both healthcare systems and patients, potentially limiting widespread adoption. Additionally, NMO is a rare and complex disease, which makes it difficult to recruit sufficient participants for large-scale clinical trials, slowing the pace of drug development and innovation. The heterogeneity of disease presentation and overlapping symptoms with multiple sclerosis also pose diagnostic challenges, which can lead to misdiagnosis and inappropriate treatment. Moreover, long-term safety data for newer therapies are still limited, which may create hesitation among clinicians and regulatory bodies when adopting these treatments on a broader scale. Lastly, the market remains highly specialized, with few pharmaceutical players involved, leading to limited competition and potential supply chain vulnerabilities. Addressing these issues will be essential to ensuring that recent advancements in NMO treatment translate into improved outcomes for patients across different healthcare environments.
This report is a detailed and comprehensive analysis for global Neuromyelitis Optica Drug market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Neuromyelitis Optica Drug market size and forecasts, in consumption value ($ Million), 2021-2032
Global Neuromyelitis Optica Drug market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
Global Neuromyelitis Optica Drug market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
Global Neuromyelitis Optica Drug market shares of main players, in revenue ($ Million), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Neuromyelitis Optica Drug
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Neuromyelitis Optica Drug market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Pfizer, Fresenius, Teva, Sandoz, Intas, Gyjtrs, NANG KUANG, Tianjin Kingyork, Baxter, CSL, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Neuromyelitis Optica Drug market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
- Glucocorticoids
- Immunotherapies
- Others
- Acute Attack
- Remission Prophylactic Treatment
- Pfizer
- Fresenius
- Teva
- Sandoz
- Intas
- Gyjtrs
- NANG KUANG
- Tianjin Kingyork
- Baxter
- CSL
- Grifols
- Octapharma
- CBOP
- North America (United States, Canada and Mexico)
- Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
- South America (Brazil, Rest of South America)
- Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
Chapter 1, to describe Neuromyelitis Optica Drug product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Neuromyelitis Optica Drug, with revenue, gross margin, and global market share of Neuromyelitis Optica Drug from 2021 to 2026.
Chapter 3, the Neuromyelitis Optica Drug competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Neuromyelitis Optica Drug market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Neuromyelitis Optica Drug.
Chapter 13, to describe Neuromyelitis Optica Drug research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Neuromyelitis Optica Drug by Type
1.3.1 Overview: Global Neuromyelitis Optica Drug Market Size by Type: 2021 Versus 2025 Versus 2032
1.3.2 Global Neuromyelitis Optica Drug Consumption Value Market Share by Type in 2025
1.3.3 Glucocorticoids
1.3.4 Immunotherapies
1.3.5 Others
1.4 Global Neuromyelitis Optica Drug Market by Application
1.4.1 Overview: Global Neuromyelitis Optica Drug Market Size by Application: 2021 Versus 2025 Versus 2032
1.4.2 Acute Attack
1.4.3 Remission Prophylactic Treatment
1.5 Global Neuromyelitis Optica Drug Market Size & Forecast
1.6 Global Neuromyelitis Optica Drug Market Size and Forecast by Region
1.6.1 Global Neuromyelitis Optica Drug Market Size by Region: 2021 VS 2025 VS 2032
1.6.2 Global Neuromyelitis Optica Drug Market Size by Region, (2021-2032)
1.6.3 North America Neuromyelitis Optica Drug Market Size and Prospect (2021-2032)
1.6.4 Europe Neuromyelitis Optica Drug Market Size and Prospect (2021-2032)
1.6.5 Asia-Pacific Neuromyelitis Optica Drug Market Size and Prospect (2021-2032)
1.6.6 South America Neuromyelitis Optica Drug Market Size and Prospect (2021-2032)
1.6.7 Middle East & Africa Neuromyelitis Optica Drug Market Size and Prospect (2021-2032)
2 COMPANY PROFILES
2.1 Pfizer
2.1.1 Pfizer Details
2.1.2 Pfizer Major Business
2.1.3 Pfizer Neuromyelitis Optica Drug Product and Solutions
2.1.4 Pfizer Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2021-2026)
2.1.5 Pfizer Recent Developments and Future Plans
2.2 Fresenius
2.2.1 Fresenius Details
2.2.2 Fresenius Major Business
2.2.3 Fresenius Neuromyelitis Optica Drug Product and Solutions
2.2.4 Fresenius Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2021-2026)
2.2.5 Fresenius Recent Developments and Future Plans
2.3 Teva
2.3.1 Teva Details
2.3.2 Teva Major Business
2.3.3 Teva Neuromyelitis Optica Drug Product and Solutions
2.3.4 Teva Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2021-2026)
2.3.5 Teva Recent Developments and Future Plans
2.4 Sandoz
2.4.1 Sandoz Details
2.4.2 Sandoz Major Business
2.4.3 Sandoz Neuromyelitis Optica Drug Product and Solutions
2.4.4 Sandoz Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2021-2026)
2.4.5 Sandoz Recent Developments and Future Plans
2.5 Intas
2.5.1 Intas Details
2.5.2 Intas Major Business
2.5.3 Intas Neuromyelitis Optica Drug Product and Solutions
2.5.4 Intas Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2021-2026)
2.5.5 Intas Recent Developments and Future Plans
2.6 Gyjtrs
2.6.1 Gyjtrs Details
2.6.2 Gyjtrs Major Business
2.6.3 Gyjtrs Neuromyelitis Optica Drug Product and Solutions
2.6.4 Gyjtrs Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2021-2026)
2.6.5 Gyjtrs Recent Developments and Future Plans
2.7 NANG KUANG
2.7.1 NANG KUANG Details
2.7.2 NANG KUANG Major Business
2.7.3 NANG KUANG Neuromyelitis Optica Drug Product and Solutions
2.7.4 NANG KUANG Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2021-2026)
2.7.5 NANG KUANG Recent Developments and Future Plans
2.8 Tianjin Kingyork
2.8.1 Tianjin Kingyork Details
2.8.2 Tianjin Kingyork Major Business
2.8.3 Tianjin Kingyork Neuromyelitis Optica Drug Product and Solutions
2.8.4 Tianjin Kingyork Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2021-2026)
2.8.5 Tianjin Kingyork Recent Developments and Future Plans
2.9 Baxter
2.9.1 Baxter Details
2.9.2 Baxter Major Business
2.9.3 Baxter Neuromyelitis Optica Drug Product and Solutions
2.9.4 Baxter Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2021-2026)
2.9.5 Baxter Recent Developments and Future Plans
2.10 CSL
2.10.1 CSL Details
2.10.2 CSL Major Business
2.10.3 CSL Neuromyelitis Optica Drug Product and Solutions
2.10.4 CSL Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2021-2026)
2.10.5 CSL Recent Developments and Future Plans
2.11 Grifols
2.11.1 Grifols Details
2.11.2 Grifols Major Business
2.11.3 Grifols Neuromyelitis Optica Drug Product and Solutions
2.11.4 Grifols Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2021-2026)
2.11.5 Grifols Recent Developments and Future Plans
2.12 Octapharma
2.12.1 Octapharma Details
2.12.2 Octapharma Major Business
2.12.3 Octapharma Neuromyelitis Optica Drug Product and Solutions
2.12.4 Octapharma Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2021-2026)
2.12.5 Octapharma Recent Developments and Future Plans
2.13 CBOP
2.13.1 CBOP Details
2.13.2 CBOP Major Business
2.13.3 CBOP Neuromyelitis Optica Drug Product and Solutions
2.13.4 CBOP Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2021-2026)
2.13.5 CBOP Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Neuromyelitis Optica Drug Revenue and Share by Players (2021-2026)
3.2 Market Share Analysis (2025)
3.2.1 Market Share of Neuromyelitis Optica Drug by Company Revenue
3.2.2 Top 3 Neuromyelitis Optica Drug Players Market Share in 2025
3.2.3 Top 6 Neuromyelitis Optica Drug Players Market Share in 2025
3.3 Neuromyelitis Optica Drug Market: Overall Company Footprint Analysis
3.3.1 Neuromyelitis Optica Drug Market: Region Footprint
3.3.2 Neuromyelitis Optica Drug Market: Company Product Type Footprint
3.3.3 Neuromyelitis Optica Drug Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Neuromyelitis Optica Drug Consumption Value and Market Share by Type (2021-2026)
4.2 Global Neuromyelitis Optica Drug Market Forecast by Type (2027-2032)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Neuromyelitis Optica Drug Consumption Value Market Share by Application (2021-2026)
5.2 Global Neuromyelitis Optica Drug Market Forecast by Application (2027-2032)
6 NORTH AMERICA
6.1 North America Neuromyelitis Optica Drug Consumption Value by Type (2021-2032)
6.2 North America Neuromyelitis Optica Drug Market Size by Application (2021-2032)
6.3 North America Neuromyelitis Optica Drug Market Size by Country
6.3.1 North America Neuromyelitis Optica Drug Consumption Value by Country (2021-2032)
6.3.2 United States Neuromyelitis Optica Drug Market Size and Forecast (2021-2032)
6.3.3 Canada Neuromyelitis Optica Drug Market Size and Forecast (2021-2032)
6.3.4 Mexico Neuromyelitis Optica Drug Market Size and Forecast (2021-2032)
7 EUROPE
7.1 Europe Neuromyelitis Optica Drug Consumption Value by Type (2021-2032)
7.2 Europe Neuromyelitis Optica Drug Consumption Value by Application (2021-2032)
7.3 Europe Neuromyelitis Optica Drug Market Size by Country
7.3.1 Europe Neuromyelitis Optica Drug Consumption Value by Country (2021-2032)
7.3.2 Germany Neuromyelitis Optica Drug Market Size and Forecast (2021-2032)
7.3.3 France Neuromyelitis Optica Drug Market Size and Forecast (2021-2032)
7.3.4 United Kingdom Neuromyelitis Optica Drug Market Size and Forecast (2021-2032)
7.3.5 Russia Neuromyelitis Optica Drug Market Size and Forecast (2021-2032)
7.3.6 Italy Neuromyelitis Optica Drug Market Size and Forecast (2021-2032)
8 ASIA-PACIFIC
8.1 Asia-Pacific Neuromyelitis Optica Drug Consumption Value by Type (2021-2032)
8.2 Asia-Pacific Neuromyelitis Optica Drug Consumption Value by Application (2021-2032)
8.3 Asia-Pacific Neuromyelitis Optica Drug Market Size by Region
8.3.1 Asia-Pacific Neuromyelitis Optica Drug Consumption Value by Region (2021-2032)
8.3.2 China Neuromyelitis Optica Drug Market Size and Forecast (2021-2032)
8.3.3 Japan Neuromyelitis Optica Drug Market Size and Forecast (2021-2032)
8.3.4 South Korea Neuromyelitis Optica Drug Market Size and Forecast (2021-2032)
8.3.5 India Neuromyelitis Optica Drug Market Size and Forecast (2021-2032)
8.3.6 Southeast Asia Neuromyelitis Optica Drug Market Size and Forecast (2021-2032)
8.3.7 Australia Neuromyelitis Optica Drug Market Size and Forecast (2021-2032)
9 SOUTH AMERICA
9.1 South America Neuromyelitis Optica Drug Consumption Value by Type (2021-2032)
9.2 South America Neuromyelitis Optica Drug Consumption Value by Application (2021-2032)
9.3 South America Neuromyelitis Optica Drug Market Size by Country
9.3.1 South America Neuromyelitis Optica Drug Consumption Value by Country (2021-2032)
9.3.2 Brazil Neuromyelitis Optica Drug Market Size and Forecast (2021-2032)
9.3.3 Argentina Neuromyelitis Optica Drug Market Size and Forecast (2021-2032)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Neuromyelitis Optica Drug Consumption Value by Type (2021-2032)
10.2 Middle East & Africa Neuromyelitis Optica Drug Consumption Value by Application (2021-2032)
10.3 Middle East & Africa Neuromyelitis Optica Drug Market Size by Country
10.3.1 Middle East & Africa Neuromyelitis Optica Drug Consumption Value by Country (2021-2032)
10.3.2 Turkey Neuromyelitis Optica Drug Market Size and Forecast (2021-2032)
10.3.3 Saudi Arabia Neuromyelitis Optica Drug Market Size and Forecast (2021-2032)
10.3.4 UAE Neuromyelitis Optica Drug Market Size and Forecast (2021-2032)
11 MARKET DYNAMICS
11.1 Neuromyelitis Optica Drug Market Drivers
11.2 Neuromyelitis Optica Drug Market Restraints
11.3 Neuromyelitis Optica Drug Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 INDUSTRY CHAIN ANALYSIS
12.1 Neuromyelitis Optica Drug Industry Chain
12.2 Neuromyelitis Optica Drug Upstream Analysis
12.3 Neuromyelitis Optica Drug Midstream Analysis
12.4 Neuromyelitis Optica Drug Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Neuromyelitis Optica Drug by Type
1.3.1 Overview: Global Neuromyelitis Optica Drug Market Size by Type: 2021 Versus 2025 Versus 2032
1.3.2 Global Neuromyelitis Optica Drug Consumption Value Market Share by Type in 2025
1.3.3 Glucocorticoids
1.3.4 Immunotherapies
1.3.5 Others
1.4 Global Neuromyelitis Optica Drug Market by Application
1.4.1 Overview: Global Neuromyelitis Optica Drug Market Size by Application: 2021 Versus 2025 Versus 2032
1.4.2 Acute Attack
1.4.3 Remission Prophylactic Treatment
1.5 Global Neuromyelitis Optica Drug Market Size & Forecast
1.6 Global Neuromyelitis Optica Drug Market Size and Forecast by Region
1.6.1 Global Neuromyelitis Optica Drug Market Size by Region: 2021 VS 2025 VS 2032
1.6.2 Global Neuromyelitis Optica Drug Market Size by Region, (2021-2032)
1.6.3 North America Neuromyelitis Optica Drug Market Size and Prospect (2021-2032)
1.6.4 Europe Neuromyelitis Optica Drug Market Size and Prospect (2021-2032)
1.6.5 Asia-Pacific Neuromyelitis Optica Drug Market Size and Prospect (2021-2032)
1.6.6 South America Neuromyelitis Optica Drug Market Size and Prospect (2021-2032)
1.6.7 Middle East & Africa Neuromyelitis Optica Drug Market Size and Prospect (2021-2032)
2 COMPANY PROFILES
2.1 Pfizer
2.1.1 Pfizer Details
2.1.2 Pfizer Major Business
2.1.3 Pfizer Neuromyelitis Optica Drug Product and Solutions
2.1.4 Pfizer Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2021-2026)
2.1.5 Pfizer Recent Developments and Future Plans
2.2 Fresenius
2.2.1 Fresenius Details
2.2.2 Fresenius Major Business
2.2.3 Fresenius Neuromyelitis Optica Drug Product and Solutions
2.2.4 Fresenius Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2021-2026)
2.2.5 Fresenius Recent Developments and Future Plans
2.3 Teva
2.3.1 Teva Details
2.3.2 Teva Major Business
2.3.3 Teva Neuromyelitis Optica Drug Product and Solutions
2.3.4 Teva Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2021-2026)
2.3.5 Teva Recent Developments and Future Plans
2.4 Sandoz
2.4.1 Sandoz Details
2.4.2 Sandoz Major Business
2.4.3 Sandoz Neuromyelitis Optica Drug Product and Solutions
2.4.4 Sandoz Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2021-2026)
2.4.5 Sandoz Recent Developments and Future Plans
2.5 Intas
2.5.1 Intas Details
2.5.2 Intas Major Business
2.5.3 Intas Neuromyelitis Optica Drug Product and Solutions
2.5.4 Intas Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2021-2026)
2.5.5 Intas Recent Developments and Future Plans
2.6 Gyjtrs
2.6.1 Gyjtrs Details
2.6.2 Gyjtrs Major Business
2.6.3 Gyjtrs Neuromyelitis Optica Drug Product and Solutions
2.6.4 Gyjtrs Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2021-2026)
2.6.5 Gyjtrs Recent Developments and Future Plans
2.7 NANG KUANG
2.7.1 NANG KUANG Details
2.7.2 NANG KUANG Major Business
2.7.3 NANG KUANG Neuromyelitis Optica Drug Product and Solutions
2.7.4 NANG KUANG Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2021-2026)
2.7.5 NANG KUANG Recent Developments and Future Plans
2.8 Tianjin Kingyork
2.8.1 Tianjin Kingyork Details
2.8.2 Tianjin Kingyork Major Business
2.8.3 Tianjin Kingyork Neuromyelitis Optica Drug Product and Solutions
2.8.4 Tianjin Kingyork Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2021-2026)
2.8.5 Tianjin Kingyork Recent Developments and Future Plans
2.9 Baxter
2.9.1 Baxter Details
2.9.2 Baxter Major Business
2.9.3 Baxter Neuromyelitis Optica Drug Product and Solutions
2.9.4 Baxter Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2021-2026)
2.9.5 Baxter Recent Developments and Future Plans
2.10 CSL
2.10.1 CSL Details
2.10.2 CSL Major Business
2.10.3 CSL Neuromyelitis Optica Drug Product and Solutions
2.10.4 CSL Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2021-2026)
2.10.5 CSL Recent Developments and Future Plans
2.11 Grifols
2.11.1 Grifols Details
2.11.2 Grifols Major Business
2.11.3 Grifols Neuromyelitis Optica Drug Product and Solutions
2.11.4 Grifols Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2021-2026)
2.11.5 Grifols Recent Developments and Future Plans
2.12 Octapharma
2.12.1 Octapharma Details
2.12.2 Octapharma Major Business
2.12.3 Octapharma Neuromyelitis Optica Drug Product and Solutions
2.12.4 Octapharma Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2021-2026)
2.12.5 Octapharma Recent Developments and Future Plans
2.13 CBOP
2.13.1 CBOP Details
2.13.2 CBOP Major Business
2.13.3 CBOP Neuromyelitis Optica Drug Product and Solutions
2.13.4 CBOP Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2021-2026)
2.13.5 CBOP Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Neuromyelitis Optica Drug Revenue and Share by Players (2021-2026)
3.2 Market Share Analysis (2025)
3.2.1 Market Share of Neuromyelitis Optica Drug by Company Revenue
3.2.2 Top 3 Neuromyelitis Optica Drug Players Market Share in 2025
3.2.3 Top 6 Neuromyelitis Optica Drug Players Market Share in 2025
3.3 Neuromyelitis Optica Drug Market: Overall Company Footprint Analysis
3.3.1 Neuromyelitis Optica Drug Market: Region Footprint
3.3.2 Neuromyelitis Optica Drug Market: Company Product Type Footprint
3.3.3 Neuromyelitis Optica Drug Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Neuromyelitis Optica Drug Consumption Value and Market Share by Type (2021-2026)
4.2 Global Neuromyelitis Optica Drug Market Forecast by Type (2027-2032)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Neuromyelitis Optica Drug Consumption Value Market Share by Application (2021-2026)
5.2 Global Neuromyelitis Optica Drug Market Forecast by Application (2027-2032)
6 NORTH AMERICA
6.1 North America Neuromyelitis Optica Drug Consumption Value by Type (2021-2032)
6.2 North America Neuromyelitis Optica Drug Market Size by Application (2021-2032)
6.3 North America Neuromyelitis Optica Drug Market Size by Country
6.3.1 North America Neuromyelitis Optica Drug Consumption Value by Country (2021-2032)
6.3.2 United States Neuromyelitis Optica Drug Market Size and Forecast (2021-2032)
6.3.3 Canada Neuromyelitis Optica Drug Market Size and Forecast (2021-2032)
6.3.4 Mexico Neuromyelitis Optica Drug Market Size and Forecast (2021-2032)
7 EUROPE
7.1 Europe Neuromyelitis Optica Drug Consumption Value by Type (2021-2032)
7.2 Europe Neuromyelitis Optica Drug Consumption Value by Application (2021-2032)
7.3 Europe Neuromyelitis Optica Drug Market Size by Country
7.3.1 Europe Neuromyelitis Optica Drug Consumption Value by Country (2021-2032)
7.3.2 Germany Neuromyelitis Optica Drug Market Size and Forecast (2021-2032)
7.3.3 France Neuromyelitis Optica Drug Market Size and Forecast (2021-2032)
7.3.4 United Kingdom Neuromyelitis Optica Drug Market Size and Forecast (2021-2032)
7.3.5 Russia Neuromyelitis Optica Drug Market Size and Forecast (2021-2032)
7.3.6 Italy Neuromyelitis Optica Drug Market Size and Forecast (2021-2032)
8 ASIA-PACIFIC
8.1 Asia-Pacific Neuromyelitis Optica Drug Consumption Value by Type (2021-2032)
8.2 Asia-Pacific Neuromyelitis Optica Drug Consumption Value by Application (2021-2032)
8.3 Asia-Pacific Neuromyelitis Optica Drug Market Size by Region
8.3.1 Asia-Pacific Neuromyelitis Optica Drug Consumption Value by Region (2021-2032)
8.3.2 China Neuromyelitis Optica Drug Market Size and Forecast (2021-2032)
8.3.3 Japan Neuromyelitis Optica Drug Market Size and Forecast (2021-2032)
8.3.4 South Korea Neuromyelitis Optica Drug Market Size and Forecast (2021-2032)
8.3.5 India Neuromyelitis Optica Drug Market Size and Forecast (2021-2032)
8.3.6 Southeast Asia Neuromyelitis Optica Drug Market Size and Forecast (2021-2032)
8.3.7 Australia Neuromyelitis Optica Drug Market Size and Forecast (2021-2032)
9 SOUTH AMERICA
9.1 South America Neuromyelitis Optica Drug Consumption Value by Type (2021-2032)
9.2 South America Neuromyelitis Optica Drug Consumption Value by Application (2021-2032)
9.3 South America Neuromyelitis Optica Drug Market Size by Country
9.3.1 South America Neuromyelitis Optica Drug Consumption Value by Country (2021-2032)
9.3.2 Brazil Neuromyelitis Optica Drug Market Size and Forecast (2021-2032)
9.3.3 Argentina Neuromyelitis Optica Drug Market Size and Forecast (2021-2032)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Neuromyelitis Optica Drug Consumption Value by Type (2021-2032)
10.2 Middle East & Africa Neuromyelitis Optica Drug Consumption Value by Application (2021-2032)
10.3 Middle East & Africa Neuromyelitis Optica Drug Market Size by Country
10.3.1 Middle East & Africa Neuromyelitis Optica Drug Consumption Value by Country (2021-2032)
10.3.2 Turkey Neuromyelitis Optica Drug Market Size and Forecast (2021-2032)
10.3.3 Saudi Arabia Neuromyelitis Optica Drug Market Size and Forecast (2021-2032)
10.3.4 UAE Neuromyelitis Optica Drug Market Size and Forecast (2021-2032)
11 MARKET DYNAMICS
11.1 Neuromyelitis Optica Drug Market Drivers
11.2 Neuromyelitis Optica Drug Market Restraints
11.3 Neuromyelitis Optica Drug Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 INDUSTRY CHAIN ANALYSIS
12.1 Neuromyelitis Optica Drug Industry Chain
12.2 Neuromyelitis Optica Drug Upstream Analysis
12.3 Neuromyelitis Optica Drug Midstream Analysis
12.4 Neuromyelitis Optica Drug Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
LIST OF TABLES
Table 1. Global Neuromyelitis Optica Drug Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Table 2. Global Neuromyelitis Optica Drug Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Table 3. Global Neuromyelitis Optica Drug Consumption Value by Region (2021-2026) & (USD Million)
Table 4. Global Neuromyelitis Optica Drug Consumption Value by Region (2027-2032) & (USD Million)
Table 5. Pfizer Company Information, Head Office, and Major Competitors
Table 6. Pfizer Major Business
Table 7. Pfizer Neuromyelitis Optica Drug Product and Solutions
Table 8. Pfizer Neuromyelitis Optica Drug Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 9. Pfizer Recent Developments and Future Plans
Table 10. Fresenius Company Information, Head Office, and Major Competitors
Table 11. Fresenius Major Business
Table 12. Fresenius Neuromyelitis Optica Drug Product and Solutions
Table 13. Fresenius Neuromyelitis Optica Drug Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 14. Fresenius Recent Developments and Future Plans
Table 15. Teva Company Information, Head Office, and Major Competitors
Table 16. Teva Major Business
Table 17. Teva Neuromyelitis Optica Drug Product and Solutions
Table 18. Teva Neuromyelitis Optica Drug Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 19. Sandoz Company Information, Head Office, and Major Competitors
Table 20. Sandoz Major Business
Table 21. Sandoz Neuromyelitis Optica Drug Product and Solutions
Table 22. Sandoz Neuromyelitis Optica Drug Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 23. Sandoz Recent Developments and Future Plans
Table 24. Intas Company Information, Head Office, and Major Competitors
Table 25. Intas Major Business
Table 26. Intas Neuromyelitis Optica Drug Product and Solutions
Table 27. Intas Neuromyelitis Optica Drug Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 28. Intas Recent Developments and Future Plans
Table 29. Gyjtrs Company Information, Head Office, and Major Competitors
Table 30. Gyjtrs Major Business
Table 31. Gyjtrs Neuromyelitis Optica Drug Product and Solutions
Table 32. Gyjtrs Neuromyelitis Optica Drug Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 33. Gyjtrs Recent Developments and Future Plans
Table 34. NANG KUANG Company Information, Head Office, and Major Competitors
Table 35. NANG KUANG Major Business
Table 36. NANG KUANG Neuromyelitis Optica Drug Product and Solutions
Table 37. NANG KUANG Neuromyelitis Optica Drug Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 38. NANG KUANG Recent Developments and Future Plans
Table 39. Tianjin Kingyork Company Information, Head Office, and Major Competitors
Table 40. Tianjin Kingyork Major Business
Table 41. Tianjin Kingyork Neuromyelitis Optica Drug Product and Solutions
Table 42. Tianjin Kingyork Neuromyelitis Optica Drug Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 43. Tianjin Kingyork Recent Developments and Future Plans
Table 44. Baxter Company Information, Head Office, and Major Competitors
Table 45. Baxter Major Business
Table 46. Baxter Neuromyelitis Optica Drug Product and Solutions
Table 47. Baxter Neuromyelitis Optica Drug Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 48. Baxter Recent Developments and Future Plans
Table 49. CSL Company Information, Head Office, and Major Competitors
Table 50. CSL Major Business
Table 51. CSL Neuromyelitis Optica Drug Product and Solutions
Table 52. CSL Neuromyelitis Optica Drug Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 53. CSL Recent Developments and Future Plans
Table 54. Grifols Company Information, Head Office, and Major Competitors
Table 55. Grifols Major Business
Table 56. Grifols Neuromyelitis Optica Drug Product and Solutions
Table 57. Grifols Neuromyelitis Optica Drug Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 58. Grifols Recent Developments and Future Plans
Table 59. Octapharma Company Information, Head Office, and Major Competitors
Table 60. Octapharma Major Business
Table 61. Octapharma Neuromyelitis Optica Drug Product and Solutions
Table 62. Octapharma Neuromyelitis Optica Drug Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 63. Octapharma Recent Developments and Future Plans
Table 64. CBOP Company Information, Head Office, and Major Competitors
Table 65. CBOP Major Business
Table 66. CBOP Neuromyelitis Optica Drug Product and Solutions
Table 67. CBOP Neuromyelitis Optica Drug Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 68. CBOP Recent Developments and Future Plans
Table 69. Global Neuromyelitis Optica Drug Revenue (USD Million) by Players (2021-2026)
Table 70. Global Neuromyelitis Optica Drug Revenue Share by Players (2021-2026)
Table 71. Breakdown of Neuromyelitis Optica Drug by Company Type (Tier 1, Tier 2, and Tier 3)
Table 72. Market Position of Players in Neuromyelitis Optica Drug, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025
Table 73. Head Office of Key Neuromyelitis Optica Drug Players
Table 74. Neuromyelitis Optica Drug Market: Company Product Type Footprint
Table 75. Neuromyelitis Optica Drug Market: Company Product Application Footprint
Table 76. Neuromyelitis Optica Drug New Market Entrants and Barriers to Market Entry
Table 77. Neuromyelitis Optica Drug Mergers, Acquisition, Agreements, and Collaborations
Table 78. Global Neuromyelitis Optica Drug Consumption Value (USD Million) by Type (2021-2026)
Table 79. Global Neuromyelitis Optica Drug Consumption Value Share by Type (2021-2026)
Table 80. Global Neuromyelitis Optica Drug Consumption Value Forecast by Type (2027-2032)
Table 81. Global Neuromyelitis Optica Drug Consumption Value by Application (2021-2026)
Table 82. Global Neuromyelitis Optica Drug Consumption Value Forecast by Application (2027-2032)
Table 83. North America Neuromyelitis Optica Drug Consumption Value by Type (2021-2026) & (USD Million)
Table 84. North America Neuromyelitis Optica Drug Consumption Value by Type (2027-2032) & (USD Million)
Table 85. North America Neuromyelitis Optica Drug Consumption Value by Application (2021-2026) & (USD Million)
Table 86. North America Neuromyelitis Optica Drug Consumption Value by Application (2027-2032) & (USD Million)
Table 87. North America Neuromyelitis Optica Drug Consumption Value by Country (2021-2026) & (USD Million)
Table 88. North America Neuromyelitis Optica Drug Consumption Value by Country (2027-2032) & (USD Million)
Table 89. Europe Neuromyelitis Optica Drug Consumption Value by Type (2021-2026) & (USD Million)
Table 90. Europe Neuromyelitis Optica Drug Consumption Value by Type (2027-2032) & (USD Million)
Table 91. Europe Neuromyelitis Optica Drug Consumption Value by Application (2021-2026) & (USD Million)
Table 92. Europe Neuromyelitis Optica Drug Consumption Value by Application (2027-2032) & (USD Million)
Table 93. Europe Neuromyelitis Optica Drug Consumption Value by Country (2021-2026) & (USD Million)
Table 94. Europe Neuromyelitis Optica Drug Consumption Value by Country (2027-2032) & (USD Million)
Table 95. Asia-Pacific Neuromyelitis Optica Drug Consumption Value by Type (2021-2026) & (USD Million)
Table 96. Asia-Pacific Neuromyelitis Optica Drug Consumption Value by Type (2027-2032) & (USD Million)
Table 97. Asia-Pacific Neuromyelitis Optica Drug Consumption Value by Application (2021-2026) & (USD Million)
Table 98. Asia-Pacific Neuromyelitis Optica Drug Consumption Value by Application (2027-2032) & (USD Million)
Table 99. Asia-Pacific Neuromyelitis Optica Drug Consumption Value by Region (2021-2026) & (USD Million)
Table 100. Asia-Pacific Neuromyelitis Optica Drug Consumption Value by Region (2027-2032) & (USD Million)
Table 101. South America Neuromyelitis Optica Drug Consumption Value by Type (2021-2026) & (USD Million)
Table 102. South America Neuromyelitis Optica Drug Consumption Value by Type (2027-2032) & (USD Million)
Table 103. South America Neuromyelitis Optica Drug Consumption Value by Application (2021-2026) & (USD Million)
Table 104. South America Neuromyelitis Optica Drug Consumption Value by Application (2027-2032) & (USD Million)
Table 105. South America Neuromyelitis Optica Drug Consumption Value by Country (2021-2026) & (USD Million)
Table 106. South America Neuromyelitis Optica Drug Consumption Value by Country (2027-2032) & (USD Million)
Table 107. Middle East & Africa Neuromyelitis Optica Drug Consumption Value by Type (2021-2026) & (USD Million)
Table 108. Middle East & Africa Neuromyelitis Optica Drug Consumption Value by Type (2027-2032) & (USD Million)
Table 109. Middle East & Africa Neuromyelitis Optica Drug Consumption Value by Application (2021-2026) & (USD Million)
Table 110. Middle East & Africa Neuromyelitis Optica Drug Consumption Value by Application (2027-2032) & (USD Million)
Table 111. Middle East & Africa Neuromyelitis Optica Drug Consumption Value by Country (2021-2026) & (USD Million)
Table 112. Middle East & Africa Neuromyelitis Optica Drug Consumption Value by Country (2027-2032) & (USD Million)
Table 113. Global Key Players of Neuromyelitis Optica Drug Upstream (Raw Materials)
Table 114. Global Neuromyelitis Optica Drug Typical Customers
Table 1. Global Neuromyelitis Optica Drug Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Table 2. Global Neuromyelitis Optica Drug Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Table 3. Global Neuromyelitis Optica Drug Consumption Value by Region (2021-2026) & (USD Million)
Table 4. Global Neuromyelitis Optica Drug Consumption Value by Region (2027-2032) & (USD Million)
Table 5. Pfizer Company Information, Head Office, and Major Competitors
Table 6. Pfizer Major Business
Table 7. Pfizer Neuromyelitis Optica Drug Product and Solutions
Table 8. Pfizer Neuromyelitis Optica Drug Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 9. Pfizer Recent Developments and Future Plans
Table 10. Fresenius Company Information, Head Office, and Major Competitors
Table 11. Fresenius Major Business
Table 12. Fresenius Neuromyelitis Optica Drug Product and Solutions
Table 13. Fresenius Neuromyelitis Optica Drug Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 14. Fresenius Recent Developments and Future Plans
Table 15. Teva Company Information, Head Office, and Major Competitors
Table 16. Teva Major Business
Table 17. Teva Neuromyelitis Optica Drug Product and Solutions
Table 18. Teva Neuromyelitis Optica Drug Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 19. Sandoz Company Information, Head Office, and Major Competitors
Table 20. Sandoz Major Business
Table 21. Sandoz Neuromyelitis Optica Drug Product and Solutions
Table 22. Sandoz Neuromyelitis Optica Drug Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 23. Sandoz Recent Developments and Future Plans
Table 24. Intas Company Information, Head Office, and Major Competitors
Table 25. Intas Major Business
Table 26. Intas Neuromyelitis Optica Drug Product and Solutions
Table 27. Intas Neuromyelitis Optica Drug Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 28. Intas Recent Developments and Future Plans
Table 29. Gyjtrs Company Information, Head Office, and Major Competitors
Table 30. Gyjtrs Major Business
Table 31. Gyjtrs Neuromyelitis Optica Drug Product and Solutions
Table 32. Gyjtrs Neuromyelitis Optica Drug Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 33. Gyjtrs Recent Developments and Future Plans
Table 34. NANG KUANG Company Information, Head Office, and Major Competitors
Table 35. NANG KUANG Major Business
Table 36. NANG KUANG Neuromyelitis Optica Drug Product and Solutions
Table 37. NANG KUANG Neuromyelitis Optica Drug Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 38. NANG KUANG Recent Developments and Future Plans
Table 39. Tianjin Kingyork Company Information, Head Office, and Major Competitors
Table 40. Tianjin Kingyork Major Business
Table 41. Tianjin Kingyork Neuromyelitis Optica Drug Product and Solutions
Table 42. Tianjin Kingyork Neuromyelitis Optica Drug Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 43. Tianjin Kingyork Recent Developments and Future Plans
Table 44. Baxter Company Information, Head Office, and Major Competitors
Table 45. Baxter Major Business
Table 46. Baxter Neuromyelitis Optica Drug Product and Solutions
Table 47. Baxter Neuromyelitis Optica Drug Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 48. Baxter Recent Developments and Future Plans
Table 49. CSL Company Information, Head Office, and Major Competitors
Table 50. CSL Major Business
Table 51. CSL Neuromyelitis Optica Drug Product and Solutions
Table 52. CSL Neuromyelitis Optica Drug Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 53. CSL Recent Developments and Future Plans
Table 54. Grifols Company Information, Head Office, and Major Competitors
Table 55. Grifols Major Business
Table 56. Grifols Neuromyelitis Optica Drug Product and Solutions
Table 57. Grifols Neuromyelitis Optica Drug Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 58. Grifols Recent Developments and Future Plans
Table 59. Octapharma Company Information, Head Office, and Major Competitors
Table 60. Octapharma Major Business
Table 61. Octapharma Neuromyelitis Optica Drug Product and Solutions
Table 62. Octapharma Neuromyelitis Optica Drug Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 63. Octapharma Recent Developments and Future Plans
Table 64. CBOP Company Information, Head Office, and Major Competitors
Table 65. CBOP Major Business
Table 66. CBOP Neuromyelitis Optica Drug Product and Solutions
Table 67. CBOP Neuromyelitis Optica Drug Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 68. CBOP Recent Developments and Future Plans
Table 69. Global Neuromyelitis Optica Drug Revenue (USD Million) by Players (2021-2026)
Table 70. Global Neuromyelitis Optica Drug Revenue Share by Players (2021-2026)
Table 71. Breakdown of Neuromyelitis Optica Drug by Company Type (Tier 1, Tier 2, and Tier 3)
Table 72. Market Position of Players in Neuromyelitis Optica Drug, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025
Table 73. Head Office of Key Neuromyelitis Optica Drug Players
Table 74. Neuromyelitis Optica Drug Market: Company Product Type Footprint
Table 75. Neuromyelitis Optica Drug Market: Company Product Application Footprint
Table 76. Neuromyelitis Optica Drug New Market Entrants and Barriers to Market Entry
Table 77. Neuromyelitis Optica Drug Mergers, Acquisition, Agreements, and Collaborations
Table 78. Global Neuromyelitis Optica Drug Consumption Value (USD Million) by Type (2021-2026)
Table 79. Global Neuromyelitis Optica Drug Consumption Value Share by Type (2021-2026)
Table 80. Global Neuromyelitis Optica Drug Consumption Value Forecast by Type (2027-2032)
Table 81. Global Neuromyelitis Optica Drug Consumption Value by Application (2021-2026)
Table 82. Global Neuromyelitis Optica Drug Consumption Value Forecast by Application (2027-2032)
Table 83. North America Neuromyelitis Optica Drug Consumption Value by Type (2021-2026) & (USD Million)
Table 84. North America Neuromyelitis Optica Drug Consumption Value by Type (2027-2032) & (USD Million)
Table 85. North America Neuromyelitis Optica Drug Consumption Value by Application (2021-2026) & (USD Million)
Table 86. North America Neuromyelitis Optica Drug Consumption Value by Application (2027-2032) & (USD Million)
Table 87. North America Neuromyelitis Optica Drug Consumption Value by Country (2021-2026) & (USD Million)
Table 88. North America Neuromyelitis Optica Drug Consumption Value by Country (2027-2032) & (USD Million)
Table 89. Europe Neuromyelitis Optica Drug Consumption Value by Type (2021-2026) & (USD Million)
Table 90. Europe Neuromyelitis Optica Drug Consumption Value by Type (2027-2032) & (USD Million)
Table 91. Europe Neuromyelitis Optica Drug Consumption Value by Application (2021-2026) & (USD Million)
Table 92. Europe Neuromyelitis Optica Drug Consumption Value by Application (2027-2032) & (USD Million)
Table 93. Europe Neuromyelitis Optica Drug Consumption Value by Country (2021-2026) & (USD Million)
Table 94. Europe Neuromyelitis Optica Drug Consumption Value by Country (2027-2032) & (USD Million)
Table 95. Asia-Pacific Neuromyelitis Optica Drug Consumption Value by Type (2021-2026) & (USD Million)
Table 96. Asia-Pacific Neuromyelitis Optica Drug Consumption Value by Type (2027-2032) & (USD Million)
Table 97. Asia-Pacific Neuromyelitis Optica Drug Consumption Value by Application (2021-2026) & (USD Million)
Table 98. Asia-Pacific Neuromyelitis Optica Drug Consumption Value by Application (2027-2032) & (USD Million)
Table 99. Asia-Pacific Neuromyelitis Optica Drug Consumption Value by Region (2021-2026) & (USD Million)
Table 100. Asia-Pacific Neuromyelitis Optica Drug Consumption Value by Region (2027-2032) & (USD Million)
Table 101. South America Neuromyelitis Optica Drug Consumption Value by Type (2021-2026) & (USD Million)
Table 102. South America Neuromyelitis Optica Drug Consumption Value by Type (2027-2032) & (USD Million)
Table 103. South America Neuromyelitis Optica Drug Consumption Value by Application (2021-2026) & (USD Million)
Table 104. South America Neuromyelitis Optica Drug Consumption Value by Application (2027-2032) & (USD Million)
Table 105. South America Neuromyelitis Optica Drug Consumption Value by Country (2021-2026) & (USD Million)
Table 106. South America Neuromyelitis Optica Drug Consumption Value by Country (2027-2032) & (USD Million)
Table 107. Middle East & Africa Neuromyelitis Optica Drug Consumption Value by Type (2021-2026) & (USD Million)
Table 108. Middle East & Africa Neuromyelitis Optica Drug Consumption Value by Type (2027-2032) & (USD Million)
Table 109. Middle East & Africa Neuromyelitis Optica Drug Consumption Value by Application (2021-2026) & (USD Million)
Table 110. Middle East & Africa Neuromyelitis Optica Drug Consumption Value by Application (2027-2032) & (USD Million)
Table 111. Middle East & Africa Neuromyelitis Optica Drug Consumption Value by Country (2021-2026) & (USD Million)
Table 112. Middle East & Africa Neuromyelitis Optica Drug Consumption Value by Country (2027-2032) & (USD Million)
Table 113. Global Key Players of Neuromyelitis Optica Drug Upstream (Raw Materials)
Table 114. Global Neuromyelitis Optica Drug Typical Customers
LIST OF FIGURES
Figure 1. Neuromyelitis Optica Drug Picture
Figure 2. Global Neuromyelitis Optica Drug Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Figure 3. Global Neuromyelitis Optica Drug Consumption Value Market Share by Type in 2025
Figure 4. Glucocorticoids
Figure 5. Immunotherapies
Figure 6. Others
Figure 7. Global Neuromyelitis Optica Drug Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 8. Neuromyelitis Optica Drug Consumption Value Market Share by Application in 2025
Figure 9. Acute Attack Picture
Figure 10. Remission Prophylactic Treatment Picture
Figure 11. Global Neuromyelitis Optica Drug Consumption Value, (USD Million): 2021 & 2025 & 2032
Figure 12. Global Neuromyelitis Optica Drug Consumption Value and Forecast (2021-2032) & (USD Million)
Figure 13. Global Market Neuromyelitis Optica Drug Consumption Value (USD Million) Comparison by Region (2021 VS 2025 VS 2032)
Figure 14. Global Neuromyelitis Optica Drug Consumption Value Market Share by Region (2021-2032)
Figure 15. Global Neuromyelitis Optica Drug Consumption Value Market Share by Region in 2025
Figure 16. North America Neuromyelitis Optica Drug Consumption Value (2021-2032) & (USD Million)
Figure 17. Europe Neuromyelitis Optica Drug Consumption Value (2021-2032) & (USD Million)
Figure 18. Asia-Pacific Neuromyelitis Optica Drug Consumption Value (2021-2032) & (USD Million)
Figure 19. South America Neuromyelitis Optica Drug Consumption Value (2021-2032) & (USD Million)
Figure 20. Middle East & Africa Neuromyelitis Optica Drug Consumption Value (2021-2032) & (USD Million)
Figure 21. Company Three Recent Developments and Future Plans
Figure 22. Global Neuromyelitis Optica Drug Revenue Share by Players in 2025
Figure 23. Neuromyelitis Optica Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2025
Figure 24. Market Share of Neuromyelitis Optica Drug by Player Revenue in 2025
Figure 25. Top 3 Neuromyelitis Optica Drug Players Market Share in 2025
Figure 26. Top 6 Neuromyelitis Optica Drug Players Market Share in 2025
Figure 27. Global Neuromyelitis Optica Drug Consumption Value Share by Type (2021-2026)
Figure 28. Global Neuromyelitis Optica Drug Market Share Forecast by Type (2027-2032)
Figure 29. Global Neuromyelitis Optica Drug Consumption Value Share by Application (2021-2026)
Figure 30. Global Neuromyelitis Optica Drug Market Share Forecast by Application (2027-2032)
Figure 31. North America Neuromyelitis Optica Drug Consumption Value Market Share by Type (2021-2032)
Figure 32. North America Neuromyelitis Optica Drug Consumption Value Market Share by Application (2021-2032)
Figure 33. North America Neuromyelitis Optica Drug Consumption Value Market Share by Country (2021-2032)
Figure 34. United States Neuromyelitis Optica Drug Consumption Value (2021-2032) & (USD Million)
Figure 35. Canada Neuromyelitis Optica Drug Consumption Value (2021-2032) & (USD Million)
Figure 36. Mexico Neuromyelitis Optica Drug Consumption Value (2021-2032) & (USD Million)
Figure 37. Europe Neuromyelitis Optica Drug Consumption Value Market Share by Type (2021-2032)
Figure 38. Europe Neuromyelitis Optica Drug Consumption Value Market Share by Application (2021-2032)
Figure 39. Europe Neuromyelitis Optica Drug Consumption Value Market Share by Country (2021-2032)
Figure 40. Germany Neuromyelitis Optica Drug Consumption Value (2021-2032) & (USD Million)
Figure 41. France Neuromyelitis Optica Drug Consumption Value (2021-2032) & (USD Million)
Figure 42. United Kingdom Neuromyelitis Optica Drug Consumption Value (2021-2032) & (USD Million)
Figure 43. Russia Neuromyelitis Optica Drug Consumption Value (2021-2032) & (USD Million)
Figure 44. Italy Neuromyelitis Optica Drug Consumption Value (2021-2032) & (USD Million)
Figure 45. Asia-Pacific Neuromyelitis Optica Drug Consumption Value Market Share by Type (2021-2032)
Figure 46. Asia-Pacific Neuromyelitis Optica Drug Consumption Value Market Share by Application (2021-2032)
Figure 47. Asia-Pacific Neuromyelitis Optica Drug Consumption Value Market Share by Region (2021-2032)
Figure 48. China Neuromyelitis Optica Drug Consumption Value (2021-2032) & (USD Million)
Figure 49. Japan Neuromyelitis Optica Drug Consumption Value (2021-2032) & (USD Million)
Figure 50. South Korea Neuromyelitis Optica Drug Consumption Value (2021-2032) & (USD Million)
Figure 51. India Neuromyelitis Optica Drug Consumption Value (2021-2032) & (USD Million)
Figure 52. Southeast Asia Neuromyelitis Optica Drug Consumption Value (2021-2032) & (USD Million)
Figure 53. Australia Neuromyelitis Optica Drug Consumption Value (2021-2032) & (USD Million)
Figure 54. South America Neuromyelitis Optica Drug Consumption Value Market Share by Type (2021-2032)
Figure 55. South America Neuromyelitis Optica Drug Consumption Value Market Share by Application (2021-2032)
Figure 56. South America Neuromyelitis Optica Drug Consumption Value Market Share by Country (2021-2032)
Figure 57. Brazil Neuromyelitis Optica Drug Consumption Value (2021-2032) & (USD Million)
Figure 58. Argentina Neuromyelitis Optica Drug Consumption Value (2021-2032) & (USD Million)
Figure 59. Middle East & Africa Neuromyelitis Optica Drug Consumption Value Market Share by Type (2021-2032)
Figure 60. Middle East & Africa Neuromyelitis Optica Drug Consumption Value Market Share by Application (2021-2032)
Figure 61. Middle East & Africa Neuromyelitis Optica Drug Consumption Value Market Share by Country (2021-2032)
Figure 62. Turkey Neuromyelitis Optica Drug Consumption Value (2021-2032) & (USD Million)
Figure 63. Saudi Arabia Neuromyelitis Optica Drug Consumption Value (2021-2032) & (USD Million)
Figure 64. UAE Neuromyelitis Optica Drug Consumption Value (2021-2032) & (USD Million)
Figure 65. Neuromyelitis Optica Drug Market Drivers
Figure 66. Neuromyelitis Optica Drug Market Restraints
Figure 67. Neuromyelitis Optica Drug Market Trends
Figure 68. Porters Five Forces Analysis
Figure 69. Neuromyelitis Optica Drug Industrial Chain
Figure 70. Methodology
Figure 71. Research Process and Data Source
Figure 1. Neuromyelitis Optica Drug Picture
Figure 2. Global Neuromyelitis Optica Drug Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Figure 3. Global Neuromyelitis Optica Drug Consumption Value Market Share by Type in 2025
Figure 4. Glucocorticoids
Figure 5. Immunotherapies
Figure 6. Others
Figure 7. Global Neuromyelitis Optica Drug Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 8. Neuromyelitis Optica Drug Consumption Value Market Share by Application in 2025
Figure 9. Acute Attack Picture
Figure 10. Remission Prophylactic Treatment Picture
Figure 11. Global Neuromyelitis Optica Drug Consumption Value, (USD Million): 2021 & 2025 & 2032
Figure 12. Global Neuromyelitis Optica Drug Consumption Value and Forecast (2021-2032) & (USD Million)
Figure 13. Global Market Neuromyelitis Optica Drug Consumption Value (USD Million) Comparison by Region (2021 VS 2025 VS 2032)
Figure 14. Global Neuromyelitis Optica Drug Consumption Value Market Share by Region (2021-2032)
Figure 15. Global Neuromyelitis Optica Drug Consumption Value Market Share by Region in 2025
Figure 16. North America Neuromyelitis Optica Drug Consumption Value (2021-2032) & (USD Million)
Figure 17. Europe Neuromyelitis Optica Drug Consumption Value (2021-2032) & (USD Million)
Figure 18. Asia-Pacific Neuromyelitis Optica Drug Consumption Value (2021-2032) & (USD Million)
Figure 19. South America Neuromyelitis Optica Drug Consumption Value (2021-2032) & (USD Million)
Figure 20. Middle East & Africa Neuromyelitis Optica Drug Consumption Value (2021-2032) & (USD Million)
Figure 21. Company Three Recent Developments and Future Plans
Figure 22. Global Neuromyelitis Optica Drug Revenue Share by Players in 2025
Figure 23. Neuromyelitis Optica Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2025
Figure 24. Market Share of Neuromyelitis Optica Drug by Player Revenue in 2025
Figure 25. Top 3 Neuromyelitis Optica Drug Players Market Share in 2025
Figure 26. Top 6 Neuromyelitis Optica Drug Players Market Share in 2025
Figure 27. Global Neuromyelitis Optica Drug Consumption Value Share by Type (2021-2026)
Figure 28. Global Neuromyelitis Optica Drug Market Share Forecast by Type (2027-2032)
Figure 29. Global Neuromyelitis Optica Drug Consumption Value Share by Application (2021-2026)
Figure 30. Global Neuromyelitis Optica Drug Market Share Forecast by Application (2027-2032)
Figure 31. North America Neuromyelitis Optica Drug Consumption Value Market Share by Type (2021-2032)
Figure 32. North America Neuromyelitis Optica Drug Consumption Value Market Share by Application (2021-2032)
Figure 33. North America Neuromyelitis Optica Drug Consumption Value Market Share by Country (2021-2032)
Figure 34. United States Neuromyelitis Optica Drug Consumption Value (2021-2032) & (USD Million)
Figure 35. Canada Neuromyelitis Optica Drug Consumption Value (2021-2032) & (USD Million)
Figure 36. Mexico Neuromyelitis Optica Drug Consumption Value (2021-2032) & (USD Million)
Figure 37. Europe Neuromyelitis Optica Drug Consumption Value Market Share by Type (2021-2032)
Figure 38. Europe Neuromyelitis Optica Drug Consumption Value Market Share by Application (2021-2032)
Figure 39. Europe Neuromyelitis Optica Drug Consumption Value Market Share by Country (2021-2032)
Figure 40. Germany Neuromyelitis Optica Drug Consumption Value (2021-2032) & (USD Million)
Figure 41. France Neuromyelitis Optica Drug Consumption Value (2021-2032) & (USD Million)
Figure 42. United Kingdom Neuromyelitis Optica Drug Consumption Value (2021-2032) & (USD Million)
Figure 43. Russia Neuromyelitis Optica Drug Consumption Value (2021-2032) & (USD Million)
Figure 44. Italy Neuromyelitis Optica Drug Consumption Value (2021-2032) & (USD Million)
Figure 45. Asia-Pacific Neuromyelitis Optica Drug Consumption Value Market Share by Type (2021-2032)
Figure 46. Asia-Pacific Neuromyelitis Optica Drug Consumption Value Market Share by Application (2021-2032)
Figure 47. Asia-Pacific Neuromyelitis Optica Drug Consumption Value Market Share by Region (2021-2032)
Figure 48. China Neuromyelitis Optica Drug Consumption Value (2021-2032) & (USD Million)
Figure 49. Japan Neuromyelitis Optica Drug Consumption Value (2021-2032) & (USD Million)
Figure 50. South Korea Neuromyelitis Optica Drug Consumption Value (2021-2032) & (USD Million)
Figure 51. India Neuromyelitis Optica Drug Consumption Value (2021-2032) & (USD Million)
Figure 52. Southeast Asia Neuromyelitis Optica Drug Consumption Value (2021-2032) & (USD Million)
Figure 53. Australia Neuromyelitis Optica Drug Consumption Value (2021-2032) & (USD Million)
Figure 54. South America Neuromyelitis Optica Drug Consumption Value Market Share by Type (2021-2032)
Figure 55. South America Neuromyelitis Optica Drug Consumption Value Market Share by Application (2021-2032)
Figure 56. South America Neuromyelitis Optica Drug Consumption Value Market Share by Country (2021-2032)
Figure 57. Brazil Neuromyelitis Optica Drug Consumption Value (2021-2032) & (USD Million)
Figure 58. Argentina Neuromyelitis Optica Drug Consumption Value (2021-2032) & (USD Million)
Figure 59. Middle East & Africa Neuromyelitis Optica Drug Consumption Value Market Share by Type (2021-2032)
Figure 60. Middle East & Africa Neuromyelitis Optica Drug Consumption Value Market Share by Application (2021-2032)
Figure 61. Middle East & Africa Neuromyelitis Optica Drug Consumption Value Market Share by Country (2021-2032)
Figure 62. Turkey Neuromyelitis Optica Drug Consumption Value (2021-2032) & (USD Million)
Figure 63. Saudi Arabia Neuromyelitis Optica Drug Consumption Value (2021-2032) & (USD Million)
Figure 64. UAE Neuromyelitis Optica Drug Consumption Value (2021-2032) & (USD Million)
Figure 65. Neuromyelitis Optica Drug Market Drivers
Figure 66. Neuromyelitis Optica Drug Market Restraints
Figure 67. Neuromyelitis Optica Drug Market Trends
Figure 68. Porters Five Forces Analysis
Figure 69. Neuromyelitis Optica Drug Industrial Chain
Figure 70. Methodology
Figure 71. Research Process and Data Source
